Skip to main content

Table 4 Effect of PPAR-γ agonists on inflammatory genes levels in the knee synovium of arthritic rats

From: Anti-inflammatory effect of antidiabetic thiazolidinediones prevents bone resorption rather than cartilage changes in experimental polyarthritis

Groups IL-1 TNF-α VEGF bFGF MCP-1
Normal controls 0.23 ± 0.20 0.13 ± 0.07 1.39 ± 0.01 0.41 ± 0.18 0.26 ± 0.14
AIA controls 1.40 ± 0.29* 1.19 ± 0.19* 3.40 ± 1.05* 5.24 ± 0.35* 1.05 ± 0.18*
AIA + ROSI 10 0.98 ± 0.06 1.39 ± 0.16 3.79 ± 0.28 4.59 ± 0.77 1.51 ± 0.22
AIA + PIO 30 0.66 ± 0.16# 0.37 ± 0.11# 4.67 ± 0.21 2.18 ± 0.61# 1.51 ± 0.21
  1. PPAR, peroxisome proliferator-activated receptor; AIA, adjuvant-induced arthritis; ROSI 10, rosiglitazone 10 mg/kg/day; PIO 30, pioglitazone 30 mg/kg/day; VEGF, vascular endothelial growth factor; bFGF, basic fibroblast growth factor; MCP-1, monocyte chemotactic protein-1. Data are expressed as means ± SEM of mRNAs of the gene of interest over L27 mRNA (n = 3 representative samples per group).
  2. *, P < 0.05 compared with normal controls; #, P < 0.05 compared with AIA controls (ANOVA and Fisher's PLSD test).